FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:270-273 January 26, 1995 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Brittenham, G. M. Related Article by Olivieri, N. F.

To the Editor: Brittenham et al. (Sept. 1 issue)¹ have shown that early treatment with deferoxamine in patients with thalassemia major can improve survival and reduce the prevalence of major complications of iron overload (such as cardiac impairment). These findings are also of considerable interest with respect to patients undergoing hemodialysis. Notwithstanding the routine use of erythropoietin in the treatment of uremic anemia, the prevalence of iron-overload complications has been reduced but not eliminated in such patients.

In a group of patients with uremia who were undergo-ing maintenance hemodialysis, we found a prevalence of iron overload of 9.6 percent (14 . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.